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ABSTRACT 
Hemophilia is a medical condition that can cause medical emergency for dentist. Hemophilia patients have high risk of 
bleeding during various dental procedures. Management of bleeding in these patients during & after surgery is the biggest 
challenge for dental surgeons. Here we present a review on management of hemophilia in dentistry for which literature 
obtained from published articles, books and manual. 
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leeding disorders are the group of disorders in 
which blood doses not clot properly due to defects 
in the blood vessels, coagulation mechanism, or 
blood platelets. An affected individual may bleed 
spontaneously or for longer than a healthy person may [1]. 
Hemophilia is the most frequently occurring congenital 
plasmatic hemorrhagic diathesis. It is a common hereditary 
bleeding disorder affecting more than 400,000 people 
worldwide. This X-linked recessive chromosomal bleeding 
disorder caused by a variety of mutations in the factor VIII 
(Hemophilia A) or factor IX (Hemophilia B). Hemophilia 
A is the most common than hemophilia B this affecting 
approximately 1:5,000 males [2].  
Scientific and Standardization Committee of the 
International Society on Thrombosis and Homeostasis 
classified hemophilia: 1. Severe form where the factor 
level is less than 1% of normal (<0.01 IU/ml); 2.  
Moderate form, where the factor level is 1–5% of normal 
(0.01–0.05 IU/ml) ; 3. Mild form with the factor level 
more than 5–40% of normal (>0.05–0.40 IU/ml  [3].Patient 
with hemophilia confront the dexterity of dentist by 
inducing intra and postoperative bleeding during treatment, 
which may be life threatening in certain cases. The 
complexities in diagnosis and handling of bleeding 
disorders contribute dynamism to dentist to avoid such 
patients in clinics.  
Hemophilia is one of the pervasive bleeding disorders 
in the world that entail attention.  Therefore, management 
of patients with hereditary bleeding disorders requires 
close cooperation between oral surgeons and a 
comprehensive hemophilia treatment center. However, 
with proper care and precautions, treatment for these 
individuals can make possible. The aim of this article is to 
review hemophilia with an emphasis on its management in 
different dental procedures. 
DIAGNOSIS OF HEMOPHILIA 
Prenatal testing – A gene test can performed during 
pregnancy. For this, a sample of placenta removes from the 
uterus and chorionic villus sampling (CVS) test perform. 
Blood test – If a doctor suspects a child may have 
hemophilia a blood test can determine whether the patient 
B 
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has hemophilia A or B. Blood tests can perform from the 
time of birth onwards [4]. 
ORAL MANIFESTATION OF HEMOPHILIA 
Hemophilia characterized by bleeding from multiple sites 
in the mouth from gingiva and extraction socket. Patients 
may also have history of multiple bleeding events over 
their lifetime, depending on the severity of hemophilia. 
Bleeding episodes are more in severe hemophilia, followed 
by moderate and mild hemophilia [5].
 
A study by Sonis 
and Musselman found an average of 29.1% bleeding 
events per year in hemophilia patients out of which 9% 
involved oral structures (labial frenum, 60%; tongue, 23%; 
buccal mucosa, 17%; gingiva and palate, 0.5%) 
[6].Therefore, for dental consideration through history is 
mandatory for proper diagnosis and management of 
hemophilia. 
 
MANAGEMENT OF HEMOPHILIA IN DIFFERENT 
DENTAL PROCEDURES: 
Hemophilia patient are at high risk of secondary bleeding 
following oral surgery. To manage this bleeding close 
cooperation between hematologists and oral surgeons is 
mandatory. Thus, International guidelines strongly follow 
with the use of clotting factor replacement therapy for all 
invasive surgical interventions.  
Anesthesia and Pain Management 
Dental pain controls with a minor analgesic such as 
paracetamol. Aspirin should not be use for pain control 
due to its inhibitory affect on platelet aggregation. There 
are no restrictions regarding the type of local anesthetic 
agent used although those with vasoconstrictors may 
provide additional local hemostasis. A buccal infiltration 
can use without any factor replacement, but the inferior 
alveolar nerve block require appropriate replacement 
therapy. It is so because there is a risk of bleeding into the 
muscles along with potential airway compromise due to a 
hematoma in the retromolar or pterygoid space (Table 1). 
Lingual nerve block also requires appropriate factor 
replacement since the injection is into an area with a rich 
plexus of blood vessels and the needle is not adjacent to 
bone [7-8]. 
Endodontics 
Endodontic treatment has generally low risk with bleeding 
disorders. I case if pulpectomy indicated working length of 
the root canal calculated meticulously to ensure that the 
instruments do not pass through the apex of the root canal. 
Bleeding t from canal is indicative of pulp tissue remaining 
in the canal in this case sodium hypochlorite use for 
irrigation followed by the use of calcium hydroxide. 
Formaldehyde-derived substances may used in cases 
where there is persistent bleeding or even before the 
pulpectomy [8]. A case report by Atara RR et al showed 
that when drainage of swelling had done with the help of 
incision under converge of antifibrinolytic agent 
(Tranexamic acid) and pressure pack, hemostasis achieved 
[9].  
Table 1: Local anesthetic techniques with requirement 
of factor replacement 
Local anesthetic techniques 
No hemostatic coverage 
required 
Hemostatic coverage 
required 
Buccal infiltration  
Intra-papillary injections 
Intra-ligamentary injections 
Inferior alveolar nerve 
block 
Lingual nerve block 
Surgery 
Surgical treatment, including dental extractions, 
periodontal surgeries, and implants must be planning to 
minimize the risk of bleeding, excessive bruising, or 
hematoma formation. Emergency surgical intervention in 
dentistry is rarely required as pain can control by using 
analgesics. 
AN ASSORTMENT OF TECHNIQUES AVAILABLE 
TO CONTROL BLEEDING 
1. Local  Measures 
Local haemostatic measures are obligatory following 
dental extraction in hemophilia patients. Local haemostatic 
agents are sutures
 
[10], collagen vlies [11], oxycellulose
 
[12], gelatin
 
[13], a fibrin glue
 
[14] and cyanoacrylate [15]. 
A study conducted by Peisker A et al to prevent late 
bleeding; absorbable sutures used and for pain control, 
non-steroidal anti-inflammatory drugs and aspirin avoided 
[16]. Wagner et al. compared use of topical haemostatic 
agents in terms of their ability to mediate platelet 
aggregation, deposition and activation in a series of in 
vitro tests. An overall activity ranking of the materials sed 
was collagen>gelatin>oxidized regenerated cellulose [17]. 
List of different local hemostatic agents is given in table 2. 
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Table 2: List of local haemostatic agents
 
[18] 
Brand Name Generic Name or description 
Gelfoam  Absorbant gelatin sponge  
Bleed-X Microporous polysaccharide  
Surgicel  Oxidized cellulose 
Tisseel  Fibrin sealant 
Thrombostat  Topical thrombin 
Cyklokapron  Tranexamic acid 
Amicar   Epsilon amino-caproic acid 
 
Table 3: Principal agents for systemic management of patients with bleeding disorders
 
[21] 
Agent 
Description Indications 
Platelets 1 unit = 50 ml; may raise count by 
6,000 
Platelet count 
< 10,000 in non-bleeding individuals 
< 50,000 pre-surgical level 
< 50,000 in actively bleeding individuals 
Non-destructive thrombocytopenia 
Fresh frozen 
plasma 
1 unit = 150–250 ml 
1 hour to thaw 
Contains factors II, VII, IX, X, XI, 
XII, XIII and heat-labile V and 
VII 
Undiagnosed bleeding disorder with active bleeding 
Severe liver disease 
When transfusing > 10 units of blood 
Immune globulin deficiency 
Cryoprecipitate 1 unit = 10–15 ml Hemophilia A, Von-Willebrand’s disease, when factor 
concentrates and DDAVP are unavailable and Fibrinogen 
deficiency 
Factor VIII 
concentrate 
1 unit raises factor VIII level 2% 
Heat-treated contains von 
Willebrand’s factor 
Recombinant and monoclonal 
technologies are pure factor VIII 
Hemophilia A with active bleeding or Pre-surgery; some cases 
of Von- Willebrand’s disease 
Factor IX 
concentrate 
1 unit raises factor IX level 1–
1.5% 
Contains factors II, VII, IX and X 
Monoclonal formulation contains 
only factor IX 
Hemophilia B, with active bleeding or Pre-surgery 
Prothrombin complex concentrates used for hemophilia A with 
inhibitor 
Desmopressin Synthetic analogue of anti-diuretic 
hormone 0.3μg/kg IV or SC 
Intranasal application 
Active bleeding or pre-surgery for some patients with von 
Willebrand’s disease, uremic bleeding of liver disease, bleeding 
esophageal varices 
Epsilon-
aminocaproic 
acid 
Antifibrinolytic: 25% oral solution 
Systemic: 75 mg/kg/6 h 
Adjunct to support clot formation for any bleeding disorder 
Tranexamic acid Antifibrinolytic: 4.8% mouth rinse 
Systemic: 25mg/kg every 8 hours 
Adjunct to support clot formation for any bleeding disorder 
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Systemic Measures 
The World Federation of Hemophilia (WFH) advises the 
use of factor concentrates to cryoprecipitate or fresh frozen 
plasma for the replacement therapy in patients with 
Hemophilia [19-20]. Doses and indication of different 
therapeutic agents used in the systemic management of the 
bleeding disorders are summarized in table 3. If 
coagulopathies are reported transfusion of appropriate 
factors to 50% to 100% of normal levels recommended. 
Recommended plasma factor levels and duration of factor 
replacement therapy vary according to the type of surgery 
as given in table 4. In hemophilia patients, additional 
postoperative factor maintenance require after extensive 
surgeries. This can be done by infusion of desmopressin, 
cryoprecipitate or fresh frozen plasma depending on the 
patient’s condition. Before planning any treatment with 
hemophilic patients always, consult with their 
hematologist.   
Table 4: Plasma factor level and duration of the 
replacement therapy needed for surgical interventions 
in patients with Hemophilia
 [22] 
 Hemophilia A Hemophilia B 
Type of 
surgery 
Desired 
Factor 
level  
Duration 
days 
Desired 
Factor 
level  
Duration 
days 
Major Surgery 
Pre-op 80-100%  60-80%  
Post-op 60-80% 1-3 40-60% 1-3 
 40-60% 4-6 30-50% 4-6 
 30-40% 7-14 20-40% 7-14 
Minor surgery 
Pre-op 50-80%  50-80%  
Post-op 30-80% 1-5 30-80% 1-5 
Prosthodontic Procedures 
Prosthodontic procedures not usually engross any risk of 
bleeding but trauma should minimized by careful post-
insertion adjustments and recall. Oral tissue handles 
dexterously during the prosthesis fabrication to reduce the 
risk of ecchymosis.   
Orthodontic Procedure 
Orthodontic therapy carried out without bleeding 
complications therefore care should take so that appliances 
not impinge on soft tissues oral hygiene should maintain 
and emphasis put on excellence [18].
 
CONCLUSION  
Hemophilic patient forms privilege group for dental 
professionals because uncontrolled bleeding during dental 
procedure may be life threatening. Therefore, anticipatory 
care of these patients is indispensable for successful dental 
practice management. Although various modalities 
available to control bleeding during dental procedures in 
these patients but a through medical history and consult 
with hematologist always be helpful to prevent bleeding 
complications.  
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